Congress Weighs Repeal of Tax Credit for Rare Disease Drugs

Long untouchable, the incentive for development of orphan drugs is now a Republican target as lawmakers consider a broad tax overhaul. KATIE THOMAS and SHEILA KAPLAN http://ift.tt/2zpkko8 http://ift.tt/2zsTueL The New York Times Health Drugs (Pharmaceuticals), Federal Taxes (US), Corporate Taxes, Medicine and Health, United States Politics and Government November 8, 2017 at 12:00AM